In fact, unlike the single compounds, the CUR + RES treatment was able to improve NK cell-mediated recognition of tumor target cells, with a concomitant upregulation of the activating receptors NKG2D and NKp30 and downregulation of the inhibitory and exhaustion receptors KIR2DL2/L3/S2, KIR3DL1 and TIGIT. The gene discussed is TIGIT; the disease is neoplasm.